Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
Cytokinetics’ aficamten improved symptoms and cardiopulmonary performance more than metoprolol in a 175-patient head-to-head study of obstructive hypertrophic cardiomyopathy (oHCM), with detailed data unveiled at the ESC Congress (Madrid).
After 24 weeks, patients on aficamten showed an average +1.1 mL/kg/min increase in peak VO₂, while the metoprolol arm declined. >50% of aficamten patients reported better physical limitation scores vs 26% on metoprolol, alongside improved quality of life. Analysts suggest aficamten could displace beta-blockers as first-line in oHCM. The U.S. FDA is expected to decide by December 2025.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-18
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
IPEC Updates Excipient Qualification Guidance
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
West Asia Tensions Squeeze Pharma Raw Materials
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
Recommend Reading
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
October Polyethylene Market Performance in China is Poor
-
Carbon Tetrachloride: Uses, Hazards, and Industrial Applications
-
Spice Up the Coop: EFSA Reaffirms Safety of Botanical Blend for Broiler Feed—With a Warning for Handlers
-
Formic Acid Market Supply Is Loose, Inventory Reduction Is Orderly
-
October polyester bottle chip prices show a trend of first declining, then stabilizing, and finally rising